Bristol Myers Squibb to acquire 2seventy bio for $286m.

Bristol Myers Squibb, a biopharmaceutical company, agreed to acquire 2seventy bio, an immuno-oncology cell therapy company, for $286m. “A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders. The strategic rationale for this acquisition is clear and today’s announcement represents the culmination of the journey for 2seventy bio. We believe that Abecma will continue to benefit from BMS’ experience and resources to ensure this important therapy is delivered to patients who need it. I would like to express my deep gratitude for current and past 2seventy team members and more broadly the dedicated community of patients, scientists, providers and partners that helped take cell and gene therapy from a complicated idea to reality for patients,” Chip Baird, 2seventy bio CEO.